<DOC>
	<DOCNO>NCT00299676</DOCNO>
	<brief_summary>The purpose observational study investigate change cognitive functioning , behavior , functional improvement Alzheimer 's disease patient treat Galantamine living home ( i.e . permanent residential care ) , obtain information regard usual clinical practice use communicate treatment expectation patient supporter .</brief_summary>
	<brief_title>An Observational Study Safety Effectiveness Galantamine Treatment Patients With Alzheimer 's Disease Over 18-month Period</brief_title>
	<detailed_description>This prospective , observational study ass change cognitive functioning , behavior , functional improvement Alzheimer 's disease patient treat Galantamine living home ( i.e . permanent residential care ) , obtain information regard usual clinical practice perform relevant specialist . There experimental component associate study observational activity part routine care . This study follow patient Alzheimer 's disease , currently permanent residential care , period 18 month . The three domain cognition , behavior function evaluate baseline use Mini-Mental State Examination ( MMSE ) and/or ADAS-Cog , abridge Instrumental Activities Daily Living ( IADL ) 14-item behavioral assessment scale . Changes 3 domain observe 3 , 6 , 12 18 month Galantamine therapy completion The Clinician Interview Based Impression Change ( CIBIC-Plus ) , abridge IADL , behavioral change , Mini-Mental State Examination/ADAS-Cog . Primary outcome determine change baseline cognition , behavior function assess 3 , 6 , 12 , 18 month measure CIBIC-Plus , abridge IADL , Mini-Mental State Examination/ADAS-Cog behavioral change . The secondary outcome development information regard treatment expectation use communicate patient supporter . Galantamine prescribe accord routine clinical practice per Product Information leaflet</detailed_description>
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Dementia</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<criteria>Patients prescribe galantamine accord approve New Zealand Data Sheet The clinical decision prescribe Galantamine must make independently decision enroll patient observational study The patient commence Galantamine treatment baseline visit Patients must currently live home ( i.e . permanent residential care ) Availability supporter regular contact patient Patients know hypersensitivity Galantamine Having severe liver impairment severe kidney impairment Suffering uncontrolled medical condition dementia Being treat , previously treat , another cholinesterase inhibitor cholinomimetics ( medication treat Alzheimer 's disease )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Alzheimer 's Disease</keyword>
	<keyword>Dementia</keyword>
	<keyword>Post Marketing</keyword>
	<keyword>Prospective Studies</keyword>
	<keyword>Longitudinal Studies</keyword>
	<keyword>New Zealand</keyword>
	<keyword>Cholinesterase Inhibitors</keyword>
	<keyword>Observational</keyword>
	<keyword>Outcomes</keyword>
</DOC>